Polymorphs are different crystalline forms of the same chemical compound. In the pharmaceutical sector, different polymorphs can exhibit different properties, such as stability, hygroscopicity, dissolution behaviour, bioavailability and processability. As a result, polymorph patents are frequently used as part of pharmaceutical lifecycle management strategies, in order to extend patent protection for a pharmaceutical compound beyond the term of the base patent.
Although the European Patent Office (EPO) recognises that a novel crystalline form of a known compound can constitute patentable subject matter, Applicants can face challenges in establishing inventive step. Over the last fifteen years, the Boards of Appeal have developed a body of case law defining the circumstances in which polymorph inventions are, and are not, likely to be considered patentable. Unfortunately, the situation is not always clear and apparently conflicting judgments are often issued.